Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ - Rosenblatt initiates coverage of Robinhood with a "Buy" rating; stock price rises

BUZZ - Rosenblatt initiates coverage of Robinhood with a "Buy" rating; stock price rises

路透社路透社2026/10/21 12:36
Show original

- ** Robinhood Markets (HOOD.O) shares rose 2.5% in premarket trading to $100.68

** Rosenblatt Securities initiated coverage on the stock with a “Buy” rating and a target price of $135

** The brokerage considers the company "one of the most promising growth companies in the financial sector"

** “The company, which started as a commission-free trading app, has now evolved into a complete financial platform, and the market still underestimates the maturity of its business development,” the brokerage added

** Out of 32 brokerages, 26 rate the stock as “Buy” or higher, 5 rate it as “Hold”, and 1 rates it as “Sell”; the median price target is $136—LSEG compiled data

** As of the previous trading session close, the stock is down 13.2% year-to-date


(To facilitate non-English speakers, Reuters has automated translation of its coverage into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides it solely for reader convenience. Reuters is not liable for any damages or losses arising from the use of automated translation.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%

Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.

智通财经•2026/10/25 02:56
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%